Is herceptin biddable at controlling subsidiary spine cancer?

Answers: That would depend on the type of cancer.

"Herceptin(R) (Trastuzumab), as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, is indicated for the adjuvant treatment of patients near HER2-overexpressing, node-positive breast cancer."

"In a clinical trial, Herceptin was proven to extend survival contained by women with HER2+ metastatic breast cancer.

As a group, when looking at the entire population of women surrounded by this trial, those who received Herceptin plus chemotherapy for HER2+ metastatic breast cancer benefited in esteemed ways.

These women lived longer than those who received chemotherapy alone
Their cancer was kept from growing for a longer time compared beside those who received chemotherapy alone
Weekly treatments with Herceptin help reduce the size of HER2+ breast cancer tumors that have spread to other parts of the body, slowed the return of these tumors,and even lowered their chances of returning

Every personality who has HER2+ breast cancer is one and only, and no cancer treatment works for every person. Your experience may vary from those of the women who participated within the clinical trial."

Your oncologist would be in the best position to recommend treatment.